Nektar Therapeutics (NasdaqCM: NKTR)
Health Care · Biotechnology · US
$39.72
-3.52% today · -24.2% 1Y
Nektar Therapeutics (NasdaqCM: NKTR) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.41B and employs 63 people.
Over the last twelve months the share price has lost 24.2%, trading between 33.40 and 109.00.
Tweenvest scores Nektar Therapeutics across four factors: quality 34/100, value 52/100, growth 0/100. Its strongest factor is value.
NKTR price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.41B
- Revenue (TTM)
- $54.59M
- P/E
- —
- EPS
- -6.47
- Dividend yield
- —
- Beta (5Y)
- 1.27
- 52-week high
- $109.00
- 52-week low
- $33.40
- Avg volume (3M)
- —
- Shares outstanding
- 34.14M
- Employees
- 63
- Next earnings
- —
About Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical firm dedicated to the global discovery and advancement of therapies addressing significant unmet medical requirements. Central to its robust pipeline is Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist. This drug is currently in Phase 3 clinical trials for metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, head and neck squamous cell carcinoma, and adjuvant melanoma. It is also being evaluated in Phase 2 for renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; Phase 1/2A for head and neck squamous cell carcinoma; Phase 1/2 for various solid tumors; and Phase 1B for COVID-19. Additionally, Nektar is developing NKTR-358, a cytokine Treg stimulant, which is in Phase 2 trials for systemic lupus erythematosus and ulcerative colitis, and Phase 1B for atopic dermatitis and psoriasis. Their portfolio further includes NKTR-255, an IL-15 receptor agonist, undergoing Phase 1/2 trials for non-Hodgkin's lymphoma, multiple myeloma, head and neck cancer, and colorectal cancer. Another investigational compound, NKTR-262, a toll-like receptor agonist, is in Phase 1/2 trials for solid tumors. The company is also advancing several other drug candidates. Nektar Therapeutics maintains strategic collaboration agreements with a multitude of pharmaceutical entities, including Takeda Pharmaceutical Company Ltd., AstraZeneca AB, UCB Pharma S.A., F. Hoffmann-La Roche Ltd, Bausch Health Companies Inc., Pfizer Inc., Amgen Inc., UCB Pharma (Biogen), Bristol-Myers Squibb Company, Baxalta Incorporated, Eli Lilly and Company, Merck KGaA, and SFJ Pharmaceuticals, Inc. Established in 1990, Nektar Therapeutics is headquartered in San Francisco, California.
- ISIN
- US6402683063
- Founded
- 1990
- Listed since
- May 3, 1994
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Hugel, Inc.KOSDAQ: A145020 | $1.47B | ₩182,800.00 | +1.50% |
| Taysha Gene Therapies, Inc.NasdaqGS: TSHA | $1.46B | $4.17 | -7.24% |
| D&D Pharmatech Inc.KOSDAQ: A347850 | $1.46B | ₩42,850.00 | -0.35% |
| Bonesupport Holding AB (publ)OM: BONEX | $1.45B | Skr242.60 | +8.98% |
| Inhibrx Biosciences, Inc.NasdaqGS: INBX | $1.40B | $90.54 | -4.70% |
| Pacific Shuanglin Bio-pharmacy Co., Ltd.SZSE: 000403 | $1.39B | CN¥9.96 | -0.99% |
| AnaptysBio, Inc.NasdaqGS: ANAB | $1.37B | $46.08 | +0.28% |
| Tyra Biosciences, Inc.NasdaqGS: TYRA | $1.37B | $19.60 | -1.71% |
Figures last refreshed Oct 11, 2026.